Arcellx Inc (ACLX)

May 21, 2025, 4:00 PM EDT - 12 days ago

Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

May 14, 2025, 9:30 AM EDT - 19 days ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

May 8, 2025, 4:00 PM EDT - 25 days ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

Apr 29, 2025, 11:45 AM EDT - 4 weeks ago

Baron Health Care Fund Q1 2025 Top Net Purchases And Sales

ISRG MASI MCK NTRA PEN TMO UNH

Apr 29, 2025, 11:30 AM EDT - 4 weeks ago

Baron Health Care Fund Q1 2025 Top Contributors And Detractors

BSX DHR GKOS INSM ISRG LLY RDNT

Mar 20, 2025, 4:00 PM EDT - 2 months ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Mar 18, 2025, 8:44 AM EDT - 2 months ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

Mar 17, 2025, 11:27 AM EDT - 2 months ago

Arcellx Impressive Safety Data Leaves Doubts

Feb 27, 2025, 4:00 PM EST - 3 months ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

Feb 26, 2025, 4:00 PM EST - 3 months ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

Dec 9, 2024, 7:50 AM EST - 6 months ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Dec 8, 2024, 11:00 PM EST - 6 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Nov 7, 2024, 4:00 PM EST - 7 months ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Nov 5, 2024, 9:00 AM EST - 7 months ago

Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study

Sep 10, 2024, 8:30 AM EDT - 9 months ago

Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma

Aug 8, 2024, 4:00 PM EDT - 10 months ago

Arcellx Provides Second Quarter 2024 Financial Results and Business Updates

Jun 26, 2024, 11:19 AM EDT - 1 year ago

Arcellx's Strategic Moves With Anito-Cel Aim To Disrupt Myeloma Market

May 9, 2024, 4:05 PM EDT - 1 year ago

Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

May 9, 2024, 4:05 PM EDT - 1 year ago

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

GILD

May 9, 2024, 4:00 PM EDT - 1 year ago

Arcellx Provides First Quarter 2024 Financial Results

May 7, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in Two Upcoming Investor Conferences

Apr 4, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference

Mar 20, 2024, 4:00 PM EDT - 1 year ago

Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Feb 29, 2024, 4:00 PM EST - 1 year ago

Arcellx to Participate at the TD Cowen 44th Annual Health Care Conference

Feb 28, 2024, 4:00 PM EST - 1 year ago

Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights

Jan 30, 2024, 5:13 AM EST - 1 year ago

Arcellx: Navigating The CAR T-Cell Revolution

Dec 8, 2023, 4:00 PM EST - 1 year ago

Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA (anito-cel) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH

Nov 15, 2023, 1:44 PM EST - 1 year ago

Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market

Nov 15, 2023, 6:23 AM EST - 1 year ago

Arcellx's stock set to surge after Gilead makes $200 million investment at a 30% premium

GILD

Nov 15, 2023, 6:00 AM EST - 1 year ago

Kite and Arcellx Announce Expansion in Strategic Partnership

GILD

Nov 15, 2023, 6:00 AM EST - 1 year ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

GILD

Nov 13, 2023, 4:00 PM EST - 1 year ago

Arcellx Provides Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

Aug 14, 2023, 4:00 PM EDT - 1 year ago

Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results

Jun 19, 2023, 7:46 PM EDT - 2 years ago

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

May 8, 2023, 4:00 PM EDT - 2 years ago

Arcellx Provides First Quarter Financial Results

Apr 13, 2023, 4:01 PM EDT - 2 years ago

Arcellx to Participate at the Canaccord Genuity 2023 Horizons in Oncology Virtual Conference

Mar 29, 2023, 4:01 PM EDT - 2 years ago

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Feb 21, 2023, 4:00 PM EST - 2 years ago

Arcellx to Participate at the H.C. Wainwright Cell Therapy Virtual Conference

Feb 2, 2023, 4:00 PM EST - 2 years ago

Arcellx to Participate in Upcoming Investor Conferences

Jan 30, 2023, 9:00 AM EST - 2 years ago

Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Jan 9, 2023, 12:46 PM EST - 2 years ago

Arcellx: The Gilead Deal Derisks And Proves Their Technology

Dec 9, 2022, 8:46 AM EST - 2 years ago

Gilead to co-develop Arcellx's multiple myeloma drug

GILD

Dec 9, 2022, 8:17 AM EST - 2 years ago

Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Dec 9, 2022, 8:17 AM EST - 2 years ago

Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress

Dec 9, 2022, 8:15 AM EST - 2 years ago

Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma

GILD

Nov 14, 2022, 4:00 PM EST - 2 years ago

Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

Nov 3, 2022, 9:00 AM EDT - 2 years ago

Arcellx Announces Presentation of New Clinical Data from Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 64th ASH Annual Meeting and Exposition

Sep 7, 2022, 4:01 PM EDT - 2 years ago

Arcellx Announces Participation at the Morgan Stanley 20th Annual Global Healthcare Conference